have helped CUNY researchers secure substantial NSF CAREER grants.
===== Grants and research =====
Between 2014 and 2019, CUNY ASRC researchers secured 126 grants totaling $61 million. Several recent grants have set records for CUNY and the CUNY Graduate Center. Faculty, postdoctoral fellows, and graduate students at the CUNY ASRC also hold several patents. Professor Kevin Gardner, director of the CUNY ASRC Structural Biology Initiative, was instrumental in the identification of hypoxia-inducible factor 2-alpha (HIF-2α) as a druggable target and the drug development efforts that led to the FDA-approved first-in-kind kidney cancer drug from Merck, belzutifan.
The CUNY ASRC is home to one of 15 Centers for Advanced Technology (CATs) designated by Empire State Development NYSTAR. Funded by a nearly $8.8 million grant, the CUNY ASRC Sensor CAT spurs academic-industry partnerships to develop sensor-based technology. Developing biomedical and environmental sensors is a particular focus, as is finding new approaches …
